Back to Search
Start Over
Efficacy and Safety of Carfilzomib at 56mg/m2with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study
- Source :
- Blood; November 2019, Vol. 134 Issue: 1, Number 1 Supplement 1 p861-861, 1p
- Publication Year :
- 2019
-
Abstract
- Introduction:Carfilzomib (20/36mg/m2) triplets with Lenalidomide-Dexamethasone (KRd), or Cyclophosphamide-Dexamethasone (KCd) are safe and effective in patients with newly diagnosed multiple myeloma(NDMM). The higher dose of 56mg/m2is effective as a doublet with Dexamethasone in the relapsed setting, but there is limited data on this dose in triplet combinations in the frontline setting.
Details
- Language :
- English
- ISSN :
- 00064971 and 15280020
- Volume :
- 134
- Issue :
- 1, Number 1 Supplement 1
- Database :
- Supplemental Index
- Journal :
- Blood
- Publication Type :
- Periodical
- Accession number :
- ejs56876396
- Full Text :
- https://doi.org/10.1182/blood-2019-127992